A Phase I/II Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by University of North Carolina, Chapel Hill
Sponsor:
Collaborators:
Argos Therapeutics
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Cynthia L Gay, MD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT02042248
First received: January 17, 2014
Last updated: February 12, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)